Intomics, a spinout from the Center for Biological Sequence Analysis (CBS) at the Technical University of Denmark, has entered a collaboration agreement with pharmaceutical company LEO Pharma, reports professional journal Ingeniøren (The Engineer). Intomics will use its expertise and biological data analysis technologies to help LEO Pharma find substances with drug potential.
The founders of Intomics see the agreement as a seal of approval and reckon the firm will attract many customers in the future.
"The technological development means that experiments generate more and more data, because it becomes cheaper and cheaper. And the challenge will be to throw the noise away and keep the essential information, and this is a need that will increase for all data-generating research areas, so we expect to have many customers in the future," said Intomics MD Thomas S. Jensen.
The MD explained that the growth in data is exponential because technologies are constantly improving. For example, measuring changes in an individual's DNA in a test previously involved one, ten or 100 changes, whereas today it is more like one million changes that are measured.
"If today you study experimentally which genomic variations correlate with a given disease by linking disease history to genomic variation data, you will typically generate terabytes of data," said Jensen, continuing:
"It naturally requires experience and expertise to handle such large amounts [of data] and that is what we have built up at CBS and now spun out in Intomics. And we expect it will make us attractive because pharmaceutical companies avoid investing in this themselves, but can focus on their core competence."
Intomics can improve biological and clinical research in areas such as biomarker discovery and optimization, extraction of biological knowledge from data, drug discovery and translational research.